Press Releases

Data pager

1 2 3

Show:

PageSizeComboBox
	select

3 pages

Data pager

1 2 3

Show:

PageSizeComboBox
	select

3 pages

12-6-2018

Diamyd Medical raises SEK 58.4 million in funds through redemption of warrants

11-26-2018

Eleven out of twelve Type 1 diabetes patients treated with intralymphatic Diamyd^® are in Partial Remission at 15 months

11-15-2018

Bulletin from Annual General Meeting of Diamyd Medical AB

11-15-2018

Diamyd Medical updates on the Company and the diabetes vaccine Diamyd^® ahead of the Annual General Meeting today

11-1-2018

Internationally renowned diabetes expert proposed to join Diamyd Medical’s Board of Directors

10-23-2018

New immunological results that support intralymphatic treatment with Diamyd^® to be presented at the Immunology of Diabetes Society Congress

10-16-2018

The Phase I/II trial with Remygen^® for the regeneration of insulin-producing cells is recruiting patients

10-3-2018

Year-End Report 17/18

9-18-2018

Diamyd Medical clarifies the goal of applying for earlier market approval for Diamyd^®

9-11-2018

Positive 15-month results with Diamyd^® in Type 1 diabetes

©

Privacy Policy | Cookie Policy

Share This Page